Infection-related adverse events comparison of Bortezomib, Carfilzomib and Ixazomib:A pharmacovigilance study based on FAERS

Bortezomib, carfilzomib and ixazomib are the most common proteasomeinhibitors (PIs) used to treat Multiple Myeloma (MM). We conducted a pharmacovigilanceanalysis using the Food and Drug Administration Adverse Event Reporting System(FAERS), aiming to offer a reference for safe and reasonable clinical use. Adverse drug reaction (ADR) signals of bortezomib, carfilzomiband ixazomib were analyzed by statistical methods including Reporting OddsRatio (ROR), Proportional Reporting Ratios (PRR), and Multi-item Gamma-PoissonShrinker (MGPS). A total of 13,977, 8263 and13296 ADRs of bortezomib, carfilzomib andixazomib were analyzed respectively from the FAERS database. The most frequent adverse reactionsignal for bortezomib was peripheral neuropathy; for carfilzomib, it was acutekidney injury; for ixazomib, it was vomiting. Then a total of 43, 23 and 10 infection-related adverseevents of bortezomib, carfilzomib and ixazomib were analyzed. The most commoninfection-related adverse event for bortezomib was cytomegalovirus infection;for carfilzomib, it was bacteremia; and for ixazomib, it was conjunctivitis. In real-world pharmacovigilance studies, PIs are associated withinfection-related adverse events, which is crucial for the safe use of PIs inthe treatment of MM. However, further research is needed to validate thehypotheses generated in this study.